Hereditary breast/ovarian cancer syndrome. A primer for obstetricians/gynecologists

Obstetrics and Gynecology Clinics of North America

Volumn 40, Issue 3, 2013, Pages 475-512

  Meaney Delman, Dana ^a   Bellcross, Cecelia A ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

BRCA1; BRCA2; Clinical management; Genetic testing; Hereditary breast cancer; Hereditary ovarian cancer

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; CA 125 ANTIGEN; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; EXEMESTANE; FLUOROURACIL; LETROZOLE; METHOTREXATE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; ORAL CONTRACEPTIVE AGENT; PLATINUM COMPLEX; PROGESTERONE RECEPTOR; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

BREAST CANCER; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CHEMOPROPHYLAXIS; DRUG RESPONSE; DRUG TARGETING; FAMILY HISTORY; GENE MUTATION; GENETIC COUNSELING; GENETIC RISK; GENETIC SCREENING; GYNECOLOGIST; HEALTH CARE QUALITY; HEREDITARY BREAST AND OVARIAN CANCER SYNDROME; HORMONE SUBSTITUTION; HUMAN; HYSTERECTOMY; LIFESTYLE; MALE BREAST CANCER; MAMMOGRAPHY; MASTECTOMY; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; OBSTETRICIAN; OVARIECTOMY; OVARY CANCER; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; SALPINGECTOMY; SALPINGOOOPHORECTOMY; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSVAGINAL ECHOGRAPHY; TUMOR SUPPRESSOR GENE;

BRCA1; BRCA2; CLINICAL MANAGEMENT; GENETIC TESTING; HEREDITARY BREAST CANCER; HEREDITARY OVARIAN CANCER;

ADULT; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; FEMALE; GYNECOLOGY; HEREDITARY BREAST AND OVARIAN CANCER SYNDROME; HUMANS; OBSTETRICS; OVARIAN NEOPLASMS; PEDIGREE; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT;

EID: 84883561044     PISSN: 08898545     EISSN: 15580474     Source Type: Journal    
DOI: 10.1016/j.ogc.2013.05.009     Document Type: Review

References (201)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013, 63(1):11-30.
2. Claus E.B., Schildkraut J.M., Thompson W.D., et al. The genetic attributable risk of breast and ovarian cancer. Cancer 1996, 77(11):2318-2324.
3. Rubinstein W. The genetics of breast cancer 2001, Blackwell Science, Malden (MA).
4. Weissman S.M., Weiss S.M., Newlin A.C. Genetic testing by cancer site: ovary. Cancer J 2012, 18(4):320-327.
5. Kurian A.W. BRCA1 and BRCA2 mutations across race and ethnicity: distribution and clinical implications. Curr Opin Obstet Gynecol 2010, 22(1):72-78.
6. Pal T., Permuth-Wey J., Betts J.A., et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer 2005, 104(12):2807-2816.
7. Risch H.A., McLaughlin J.R., Cole D.E., et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. JNatl Cancer Inst 2006, 98(23):1694-1706.
8. Group ABCS Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Anglian Breast Cancer Study Group. Br J Cancer 2000, 83(10):1301-1308.
9. Miki Y., Swensen J., Shattuck-Eidens D., et al. Astrong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994, 266(5182):66-71.
10. Wooster R., Bignell G., Lancaster J., et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995, 378(6559):789-792.
11. Nelson H.D., Huffman L.H., Fu R., et al. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med 2005, 143(5):362-379.
12. Risch H.A., McLaughlin J.R., Cole D.E., et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 2001, 68(3):700-710.
13. Roa B.B., Boyd A.A., Volcik K., et al. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 1996, 14(2):185-187.
14. Callahan M.J., Crum C.P., Medeiros F., et al. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. JClin Oncol 2007, 25(25):3985-3990.
15. Medeiros F., Muto M.G., Lee Y., et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol 2006, 30(2):230-236.
16. Vicus D., Finch A., Cass I., et al. Prevalence of BRCA1 and BRCA2 germ line mutations among women with carcinoma of the fallopian tube. Gynecol Oncol 2010, 118(3):299-302.
17. Reitsma W., de Bock G.H., Oosterwijk J.C., et al. Support of the 'fallopian tube hypothesis' in a prospective series of risk-reducing salpingo-oophorectomy specimens. Eur J Cancer 2013, 49(1):132-141.
18. Chen S., Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. JClin Oncol 2007, 25(11):1329-1333.
19. U.S.Preventive Services Task Force Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement. Ann Intern Med 2005, 143(5):355-361.
20. American College of Obstetricians and Gynecologists, ACOG Committee on Practice Bulletins-Gynecology, ACOG Committee on Genetics, Society of Gynecologic Oncologists ACOG Practice Bulletin No. 103: hereditary breast and ovarian cancer syndrome. Obstet Gynecol 2009, 113(4):957-966.
21. Lancaster J.M., Powell C.B., Kauff N.D., et al. Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol 2007, 107(2):159-162.
22. National Comprehensive Cancer Network. Clinical practice guidelines in oncology. Genetic/familial high-risk assessment: breast and ovarian. 2013. Available at: Accessed March 1, 2013. http://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf.
23. Hoskins K.F., Zwaagstra A., Ranz M. Validation of a tool for identifying women at high risk for hereditary breast cancer in population-based screening. Cancer 2006, 107(8):1769-1776.
24. Teller P., Hoskins K.F., Zwaagstra A., et al. Validation of the pedigree assessment tool (PAT) in families with BRCA1 and BRCA2 mutations. Ann Surg Oncol 2010, 17(1):240-246.
25. Bellcross C. Further development and evaluation of a breast/ovarian cancer genetics referral screening tool. Genet Med 2010, 12(4):240.
26. Bellcross C.A., Lemke A.A., Pape L.S., et al. Evaluation of a breast/ovarian cancer genetics referral screening tool in a mammography population. Genet Med 2009, 11(11):783-789.
27. Gail M.H., Brinton L.A., Byar D.P., et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. JNatl Cancer Inst 1989, 81(24):1879-1886.
28. Cancer Co. Cancer Program Standards 2012: ensuring patient-centered care. 2012; V1.1. Available at: Accessed March 1, 2012. http://www.facs.org/cancer/coc/programstandards2012.pdf.
29. Berliner J.L., Fay A.M., Cummings S.A., et al. NSGC practice guideline: risk assessment and genetic counseling for hereditary breast and ovarian cancer. JGenet Couns 2013, 22(2):155-163.
30. Riley B.D., Culver J.O., Skrzynia C., et al. Essential elements of genetic cancer risk assessment, counseling, and testing: updated recommendations of the National Society of Genetic Counselors. JGenet Couns 2012, 21(2):151-161.
31. Robson M.E., Storm C.D., Weitzel J., et al. American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. JClin Oncol 2010, 28(5):893-901.
32. Matloff E.T., Brierley K.L. The double-helix derailed: the story of the BRCA patent. Lancet 2010, 376(9738):314-315.
33. Domchek S.M., Gaudet M.M., Stopfer J.E., et al. Breast cancer risks in individuals testing negative for a known family mutation in BRCA1 or BRCA2. Breast Cancer Res Treat 2010, 119(2):409-414.
34. Kauff N.D., Mitra N., Robson M.E., et al. Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families. JNatl Cancer Inst 2005, 97(18):1382-1384.
35. Petrucelli N., Daly M.B., Feldman G.L. Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2. Genet Med 2010, 12(5):245-259.
36. Shannon K.M., Chittenden A. Genetic testing by cancer site: breast. Cancer J 2012, 18(4):310-319.
37. Weitzel J.N., Blazer K.R., Macdonald D.J., et al. Genetics, genomics, and cancer risk assessment: State of the Art and Future Directions in the Era of Personalized Medicine. CA Cancer J Clin 2011, 61:327-359.
38. Shuen A.Y., Foulkes W.D. Inherited mutations in breast cancer genes-risk and response. JMammary Gland Biol Neoplasia 2011, 16(1):3-15.
39. Eng C., Sharp R.R. Bioethical and clinical dilemmas of direct-to-consumer personal genomic testing: the problem of misattributed equivalence. Sci Transl Med 2010, 2(17):1-5.
40. Wacholder S., Hartge P., Prentice R., et al. Performance of common genetic variants in breast-cancer risk models. NEngl J Med 2010, 362(11):986-993.
41. Brandt A., Bermejo J.L., Sundquist J., et al. Age of onset in familial cancer. Ann Oncol 2008, 19(12):2084-2088.
42. Forman A.D., Hall M.J. Influence of race/ethnicity on genetic counseling and testing for hereditary breast and ovarian cancer. Breast J 2009, 15(Suppl 1):S56-S62.
43. Kieran S., Loescher L.J., Lim K.H. The role of financial factors in acceptance of clinical BRCA genetic testing. Genet Test 2007, 11(1):101-110.
44. Lowstuter K.J., Sand S., Blazer K.R., et al. Influence of genetic discrimination perceptions and knowledge on cancer genetics referral practice among clinicians. Genet Med 2008, 10(9):691-698.
45. Centers for Disease Control and Prevention Health plan implementation of U.S. Preventive Services Task Force A and B recommendations-Colorado, 2010. MMWR Morb Mortal Wkly Rep 2011, 60(39):1348-1350.
46. Institute NHGR. Genetic discrimination. Available at: Accessed March 1, 2013. http://www.genome.gov/10002077.
47. Hall J.P., Moore J.M. The Affordable Care Act's pre-existing condition insurance plan: enrollment, costs, and lessons for reform. Issue Brief (Commonw Fund) 2012, 24:1-13.
48. Hamilton J.G., Lobel M., Moyer A. Emotional distress following genetic testing for hereditary breast and ovarian cancer: a meta-analytic review. Health Psychol 2009, 28(4):510-518.
49. Lerman C., Hughes C., Lemon S.J., et al. What you don't know can hurt you: adverse psychologic effects in members of BRCA1-linked and BRCA2-linked families who decline genetic testing. JClin Oncol 1998, 16(5):1650-1654.
50. Lynch H.T., Snyder C., Lynch J.F., et al. Patient responses to the disclosure of BRCA mutation tests in hereditary breast-ovarian cancer families. Cancer Genet Cytogenet 2006, 165(2):91-97.
51. Litton J.K., Ready K., Chen H., et al. Earlier age of onset of BRCA mutation-related cancers in subsequent generations. Cancer 2012, 118(2):321-325.
52. Easton D.F., Ford D., Bishop D.T. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 1995, 56(1):265-271.
53. Ford D., Easton D.F., Stratton M., et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998, 62(3):676-689.
54. Antoniou A., Pharoah P.D., Narod S., et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003, 72(5):1117-1130.
55. Hamilton R., Hurley K.E. Conditions and consequences of a BRCA mutation in young, single women of childbearing age. Oncol Nurs Forum 2010, 37(5):627-634.
56. Evans D.G., Lalloo F., Ashcroft L., et al. Uptake of risk-reducing surgery in unaffected women at high risk of breast and ovarian cancer is risk, age, and time dependent. Cancer Epidemiol Biomarkers Prev 2009, 18(8):2318-2324.
57. Donnelly L.S., Watson M., Moynihan C., et al. Reproductive decision-making in young female carriers of a BRCA mutation. Hum Reprod 2013, 28(4):1006-1012.
58. Sigal B.M., Munoz D.F., Kurian A.W., et al. Asimulation model to predict the impact of prophylactic surgery and screening on the life expectancy of BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev 2012, 21(7):1066-1077.
59. Schackmann E.A., Munoz D.F., Mills M.A., et al. Feasibility evaluation of an online tool to guide decisions for BRCA1/2 mutation carriers. Fam Cancer 2013, 12(1):65-73.
60. Brose M.S., Rebbeck T.R., Calzone K.A., et al. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. JNatl Cancer Inst 2002, 94(18):1365-1372.
61. Metcalfe K., Lynch H.T., Ghadirian P., et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. JClin Oncol 2004, 22(12):2328-2335.
62. Tung N. Management of women with BRCA mutations: a 41-year-old woman with a BRCA mutation and a recent history of breast cancer. JAMA 2011, 305(21):2211-2220.
63. Stucky C.C., Gray R.J., Wasif N., et al. Increase in contralateral prophylactic mastectomy: echoes of a bygone era? Surgical trends for unilateral breast cancer. Ann Surg Oncol 2010, 17(Suppl 3):330-337.
64. Verhoog L.C., Brekelmans C.T., Seynaeve C., et al. Contralateral breast cancer risk is influenced by the age at onset in BRCA1-associated breast cancer. Br J Cancer 2000, 83(3):384-386.
65. Pierce L.J., Haffty B.G. Radiotherapy in the treatment of hereditary breast cancer. Semin Radiat Oncol 2011, 21(1):43-50.
66. Reding K.W., Bernstein J.L., Langholz B.M., et al. Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer. Breast Cancer Res Treat 2010, 123(2):491-498.
67. Thompson D., Easton D. Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Hum Genet 2001, 68(2):410-419.
68. Giordano S.H., Cohen D.S., Buzdar A.U., et al. Breast carcinoma in men: a population-based study. Cancer 2004, 101(1):51-57.
69. Levy-Lahad E., Friedman E. Cancer risks among BRCA1 and BRCA2 mutation carriers. Br J Cancer 2007, 96(1):11-15.
70. Simchoni S., Friedman E., Kaufman B., et al. Familial clustering of site-specific cancer risks associated with BRCA1 and BRCA2 mutations in the Ashkenazi Jewish population. Proc Natl Acad Sci USA 2006, 103(10):3770-3774.
71. Antoniou A.C., Sinilnikova O.M., Simard J., et al. RAD51 135G->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am J Hum Genet 2007, 81(6):1186-1200.
72. Metcalfe K., Lubinski J., Lynch H.T., et al. Family history of cancer and cancer risks in women with BRCA1 or BRCA2 mutations. JNatl Cancer Inst 2010, 102(24):1874-1878.
73. Kotsopoulos J., Lubinski J., Lynch H.T., et al. Age at menarche and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Cancer Causes Control 2005, 16(6):667-674.
74. Nedelcu R., Liede A., Aube J., et al. BRCA mutations in Italian breast/ovarian cancer families. Eur J Hum Genet 2002, 10(2):150-152.
75. Cullinane C.A., Lubinski J., Neuhausen S.L., et al. Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers. Int J Cancer 2005, 117(6):988-991.
76. Kotsopoulos J., Lubinski J., Salmena L., et al. Breastfeeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res 2012, 14(2):R42.
77. Antoniou A.C., Rookus M., Andrieu N., et al. Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: results from the International BRCA1/2 Carrier Cohort Study. Cancer Epidemiol Biomarkers Prev 2009, 18(2):601-610.
78. Andrieu N., Goldgar D.E., Easton D.F., et al. Pregnancies, breast-feeding, and breast cancer risk in the International BRCA1/2 Carrier Cohort Study (IBCCS). JNatl Cancer Inst 2006, 98(8):535-544.
79. King M.C., Marks J.H., Mandell J.B. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003, 302(5645):643-646.
80. Kotsopoulos J., Olopado O.I., Ghadirian P., et al. Changes in body weight and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res 2005, 7(5):R833-R843.
81. Cibula D., Zikan M., Dusek L., et al. Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis. Expert Rev Anticancer Ther 2011, 11(8):1197-1207.
82. Iodice S., Barile M., Rotmensz N., et al. Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis. Eur J Cancer 2010, 46(12):2275-2284.
83. Robson M.E., Chappuis P.O., Satagopan J., et al. Acombined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res 2004, 6(1):R8-R17.
84. Rennert G., Bisland-Naggan S., Barnett-Griness O., et al. Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. NEngl J Med 2007, 357(2):115-123.
85. Brekelmans C.T., Tilanus-Linthorst M.M., Seynaeve C., et al. Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases. Eur J Cancer 2007, 43(5):867-876.
86. Bordeleau L., Panchal S., Goodwin P. Prognosis of BRCA-associated breast cancer: a summary of evidence. Breast Cancer Res Treat 2010, 119(1):13-24.
87. Mavaddat N., Barrowdale D., Andrulis I.L., et al. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev 2012, 21(1):134-147.
88. Lakhani S.R., Van De Vijver M.J., Jacquemier J., et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. JClin Oncol 2002, 20(9):2310-2318.
89. Lakhani S.R., Reis-Filho J.S., Fulford L., et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 2005, 11(14):5175-5180.
90. Wevers M.R., Hahn D.E., Verhoef S., et al. Breast cancer genetic counseling after diagnosis but before treatment: a pilot study on treatment consequences and psychological impact. Patient Educ Couns 2012, 89(1):89-95.
91. Chung A., Huynh K., Lawrence C., et al. Comparison of patient characteristics and outcomes of contralateral prophylactic mastectomy and unilateral total mastectomy in breast cancer patients. Ann Surg Oncol 2012, 19(8):2600-2606.
92. Pierce L.J., Phillips K.A., Griffith K.A., et al. Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy. Breast Cancer Res Treat 2010, 121(2):389-398.
93. Heemskerk-Gerritsen B.A., Kriege M., Seynaeve C. Association of risk-reducing surgery with cancer risks and mortality in BRCA mutation carriers. JAMA 2010, 304(24):2695. [author reply: 2695-6].
94. van Sprundel T.C., Schmidt M.K., Rookus M.A., et al. Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers. Br J Cancer 2005, 93(3):287-292.
95. Kriege M., Seynaeve C., Meijers-Heijboer H., et al. Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers. JClin Oncol 2009, 27(23):3764-3771.
96. Tutt A., Robson M., Garber J.E., et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010, 376(9737):235-244.
97. Warner E., Plewes D.B., Hill K.A., et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 2004, 292(11):1317-1325.
98. Kuhl C.K., Schrading S., Leutner C.C., et al. Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. JClin Oncol 2005, 23(33):8469-8476.
99. Lowry K.P., Lee J.M., Kong C.Y., et al. Annual screening strategies in BRCA1 and BRCA2 gene mutation carriers: a comparative effectiveness analysis. Cancer 2012, 118(8):2021-2030.
100. Saslow D., Boetes C., Burke W., et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 2007, 57(2):75-89.
101. Warner E., Hill K., Causer P., et al. Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging. JClin Oncol 2011, 29(13):1664-1669.
102. Cott Chubiz J.E., Lee J.M., Gilmore M.E., et al. Cost-effectiveness of alternating magnetic resonance imaging and digital mammography screening in BRCA1 and BRCA2 gene mutation carriers. Cancer 2013, 119(6):1266-1276.
103. Kriege M., Brekelmans C.T., Boetes C., et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. NEngl J Med 2004, 351(5):427-437.
104. Leach M.O., Boggis C.R., Dixon A.K., et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet 2005, 365(9473):1769-1778.
105. Kriege M., Brekelmans C.T., Obdeijn I.M., et al. Factors affecting sensitivity and specificity of screening mammography and MRI in women with an inherited risk for breast cancer. Breast Cancer Res Treat 2006, 100(1):109-119.
106. Passaperuma K., Warner E., Causer P.A., et al. Long-term results of screening with magnetic resonance imaging in women with BRCA mutations. Br J Cancer 2012, 107(1):24-30.
107. Robson M., Offit K. Clinical practice. Management of an inherited predisposition to breast cancer. NEngl J Med 2007, 357(2):154-162.
108. Domchek S.M., Friebel T.M., Singer C.F., et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 2010, 304(9):967-975.
109. Hartmann L.C., Sellers T.A., Schaid D.J., et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. JNatl Cancer Inst 2001, 93(21):1633-1637.
110. Meijers-Heijboer H., van Geel B., van Putten W.L., et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. NEngl J Med 2001, 345(3):159-164.
111. Rebbeck T.R., Friebel T., Lynch H.T., et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. JClin Oncol 2004, 22(6):1055-1062.
112. Metcalfe K.A., Birenbaum-Carmeli D., Lubinski J., et al. International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. Int J Cancer 2008, 122(9):2017-2022.
113. Eisen A., Lubinski J., Klijn J., et al. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. JClin Oncol 2005, 23(30):7491-7496.
114. Kauff N.D., Domchek S.M., Friebel T.M., et al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. JClin Oncol 2008, 26(8):1331-1337.
115. Rebbeck T.R., Kauff N.D., Domchek S.M. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. JNatl Cancer Inst 2009, 101(2):80-87.
116. Fisher B., Costantino J.P., Wickerham D.L., et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. JNatl Cancer Inst 1998, 90(18):1371-1388.
117. King M.C., Wieand S., Hale K., et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 2001, 286(18):2251-2256.
118. Gronwald J., Tung N., Foulkes W.D., et al. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. Int J Cancer 2006, 118(9):2281-2284.
119. Metcalfe K.A., Snyder C., Seidel J., et al. The use of preventive measures among healthy women who carry a BRCA1 or BRCA2 mutation. Fam Cancer 2005, 4(2):97-103.
120. Uray I.P., Brown P.H. Chemoprevention of hormone receptor-negative breast cancer: new approaches needed. Recent Results Cancer Res 2011, 188:147-162.
121. Long K.C., Kauff N.D. Hereditary ovarian cancer: recent molecular insights and their impact on screening strategies. Curr Opin Oncol 2011, 23(5):526-530.
122. Levine D.A., Argenta P.A., Yee C.J., et al. Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations. JClin Oncol 2003, 21(22):4222-4227.
123. Piver M.S., Jishi M.F., Tsukada Y., et al. Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer. A report of the Gilda Radner Familial Ovarian Cancer Registry. Cancer 1993, 71(9):2751-2755.
124. Evans D.G., Gaarenstroom K.N., Stirling D., et al. Screening for familial ovarian cancer: poor survival of BRCA1/2 related cancers. JMed Genet 2009, 46(9):593-597.
125. Dann R.B., Kelley J.L., Zorn K.K. Strategies for ovarian cancer prevention. Obstet Gynecol Clin North Am 2007, 34(4):667-686.
126. Lakhani S.R., Manek S., Penault-Llorca F., et al. Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. Clin Cancer Res 2004, 10(7):2473-2481.
127. Berchuck A., Heron K.A., Carney M.E., et al. Frequency of germline and somatic BRCA1 mutations in ovarian cancer. Clin Cancer Res 1998, 4(10):2433-2437.
128. Powell C.B., Kenley E., Chen L.M., et al. Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. JClin Oncol 2005, 23(1):127-132.
129. Shaw P.A., Rouzbahman M., Pizer E.S., et al. Candidate serous cancer precursors in fallopian tube epithelium of BRCA1/2 mutation carriers. Mod Pathol 2009, 22(9):1133-1138.
130. Aziz S., Kuperstein G., Rosen B., et al. Agenetic epidemiological study of carcinoma of the fallopian tube. Gynecol Oncol 2001, 80(3):341-345.
131. Boyd J., Sonoda Y., Federici M.G., et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 2000, 283(17):2260-2265.
132. Bolton K.L., Chenevix-Trench G., Goh C., et al. Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA 2012, 307(4):382-390.
133. Cass I., Baldwin R.L., Varkey T., et al. Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 2003, 97(9):2187-2195.
134. Lacour R.A., Westin S.N., Meyer L.A., et al. Improved survival in non-Ashkenazi Jewish ovarian cancer patients with BRCA1 and BRCA2 gene mutations. Gynecol Oncol 2011, 121(2):358-363.
135. Tan D.S., Rothermundt C., Thomas K., et al. "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. JClin Oncol 2008, 26(34):5530-5536.
136. Hyman D.M., Zhou Q., Iasonos A., et al. Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer. Cancer 2012, 118(15):3703-3709.
137. Liu G., Yang D., Sun Y., et al. Differing clinical impact of BRCA1 and BRCA2 mutations in serous ovarian cancer. Pharmacogenomics 2012, 13(13):1523-1535.
138. Fong P.C., Yap T.A., Boss D.S., et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. JClin Oncol 2010, 28(15):2512-2519.
139. Fong P.C., Boss D.S., Yap T.A., et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. NEngl J Med 2009, 361(2):123-134.
140. Pennington K.P., Swisher E.M. Hereditary ovarian cancer: beyond the usual suspects. Gynecol Oncol 2012, 124(2):347-353.
141. Wilkinson-Ryan I., Mutch D. Areview of iniparib in ovarian cancer. Expert Opin Investig Drugs 2013, 22(3):399-405.
142. Ratner E.S., Sartorelli A.C., Lin Z.P. Poly (ADP-ribose) polymerase inhibitors: on the horizon of tailored and personalized therapies for epithelial ovarian cancer. Curr Opin Oncol 2012, 24(5):564-571.
143. Woodward E.R., Sleightholme H.V., Considine A.M., et al. Annual surveillance by CA125 and transvaginal ultrasound for ovarian cancer in both high-risk and population risk women is ineffective. BJOG 2007, 114(12):1500-1509.
144. van der Velde N.M., Mourits M.J., Arts H.J., et al. Time to stop ovarian cancer screening in BRCA1/2 mutation carriers?. Int J Cancer 2009, 124(4):919-923.
145. Clarke-Pearson D.L. Clinical practice. Screening for ovarian cancer. NEngl J Med 2009, 361(2):170-177.
146. Kauff N.D., Satagopan J.M., Robson M.E., et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. NEngl J Med 2002, 346(21):1609-1615.
147. Rhiem K., Foth D., Wappenschmidt B., et al. Risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers. Arch Gynecol Obstet 2011, 283(3):623-627.
148. Kenkhuis M.J., de Bock G.H., Elferink P.O., et al. Short-term surgical outcome and safety of risk reducing salpingo-oophorectomy in BRCA1/2 mutation carriers. Maturitas 2010, 66(3):310-314.
149. Lu K.H., Garber J.E., Cramer D.W., et al. Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy. JClin Oncol 2000, 18(14):2728-2732.
150. Finch A., Beiner M., Lubinski J., et al. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. JAMA 2006, 296(2):185-192.
151. Rebbeck T.R., Friebel T., Wagner T., et al. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. JClin Oncol 2005, 23(31):7804-7810.
152. Leeper K., Garcia R., Swisher E., et al. Pathologic findings in prophylactic oophorectomy specimens in high-risk women. Gynecol Oncol 2002, 87(1):52-56.
153. McLaughlin J.R., Risch H.A., Lubinski J., et al. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet Oncol 2007, 8(1):26-34.
154. Mingels M.J., Roelofsen T., van der Laak J.A., et al. Tubal epithelial lesions in salpingo-oophorectomy specimens of BRCA-mutation carriers and controls. Gynecol Oncol 2012, 127(1):88-93.
155. Agoff S.N., Mendelin J.E., Grieco V.S., et al. Unexpected gynecologic neoplasms in patients with proven or suspected BRCA-1 or -2 mutations: implications for gross examination, cytology, and clinical follow-up. Am J Surg Pathol 2002, 26(2):171-178.
156. Landon G., Stewart J., Deavers M., et al. Peritoneal washing cytology in patients with BRCA1 or BRCA2 mutations undergoing risk-reducing salpingo-oophorectomies: a 10-year experience and reappraisal of its clinical utility. Gynecol Oncol 2012, 125(3):683-686.
157. Rebbeck T.R., Lynch H.T., Neuhausen S.L., et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. NEngl J Med 2002, 346(21):1616-1622.
158. Finch A., Metcalfe K.A., Chiang J.K., et al. The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation. Gynecol Oncol 2011, 121(1):163-168.
159. Finch A., Metcalfe K.A., Chiang J., et al. The impact of prophylactic salpingo-oophorectomy on quality of life and psychological distress in women with a BRCA mutation. Psychooncology 2013, 22(1):212-219.
160. Finch A., Evans G., Narod S.A. BRCA carriers, prophylactic salpingo-oophorectomy and menopause: clinical management considerations and recommendations. Womens Health (Lond Engl) 2012, 8(5):543-555.
161. Finch A., Narod S.A. Quality of life and health status after prophylactic salpingo-oophorectomy in women who carry a BRCA mutation: a review. Maturitas 2011, 70(3):261-265.
162. Campfield Bonadies D., Moyer A., Matloff E.T. What I wish I'd known before surgery: BRCA carriers' perspectives after bilateral salipingo-oophorectomy. Fam Cancer 2011, 10(1):79-85.
163. Cohen J.V., Chiel L., Boghossian L., et al. Non-cancer endpoints in BRCA1/2 carriers after risk-reducing salpingo-oophorectomy. Fam Cancer 2012, 11(1):69-75.
164. Challberg J., Ashcroft L., Lalloo F., et al. Menopausal symptoms and bone health in women undertaking risk reducing bilateral salpingo-oophorectomy: significant bone health issues in those not taking HRT. Br J Cancer 2011, 105(1):22-27.
165. Jacoby V.L., Grady D., Wactawski-Wende J., et al. Oophorectomy vs ovarian conservation with hysterectomy: cardiovascular disease, hip fracture, and cancer in the Women's Health Initiative Observational Study. Arch Intern Med 2011, 171(8):760-768.
166. Vesco K.K., Marshall L.M., Nelson H.D., et al. Surgical menopause and nonvertebral fracture risk among older US women. Menopause 2012, 19(5):510-516.
167. Banks E., Reeves G.K., Beral V., et al. Hip fracture incidence in relation to age, menopausal status, and age at menopause: prospective analysis. PLoS Med 2009, 6(11):e1000181.
168. Rivera C.M., Grossardt B.R., Rhodes D.J., et al. Increased cardiovascular mortality after early bilateral oophorectomy. Menopause 2009, 16(1):15-23.
169. Colditz G.A., Willett W.C., Stampfer M.J., et al. Menopause and the risk of coronary heart disease in women. NEngl J Med 1987, 316(18):1105-1110.
170. Atsma F., Bartelink M.L., Grobbee D.E., et al. Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis. Menopause 2006, 13(2):265-279.
171. Beiner M.E., Finch A., Rosen B., et al. The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study. Gynecol Oncol 2007, 104(1):7-10.
172. Karlan B.Y., Baldwin R.L., Lopez-Luevanos E., et al. Peritoneal serous papillary carcinoma, a phenotypic variant of familial ovarian cancer: implications for ovarian cancer screening. Am J Obstet Gynecol 1999, 180(4):917-928.
173. Pennington K.P., Walsh T., Lee M., et al. BRCA1, TP53, and CHEK2 germline mutations in uterine serous carcinoma. Cancer 2013, 119(2):332-338.
174. Gabriel C.A., Tigges-Cardwell J., Stopfer J., et al. Use of total abdominal hysterectomy and hormone replacement therapy in BRCA1 and BRCA2 mutation carriers undergoing risk-reducing salpingo-oophorectomy. Fam Cancer 2009, 8(1):23-28.
175. Chlebowski R.T., Kuller L.H., Prentice R.L., et al. Breast cancer after use of estrogen plus progestin in postmenopausal women. NEngl J Med 2009, 360(6):573-587.
176. Eisen A., Lubinski J., Gronwald J., et al. Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. JNatl Cancer Inst 2008, 100(19):1361-1367.
177. Narod S.A., Sun P., Risch H.A. Ovarian cancer, oral contraceptives, and BRCA mutations. NEngl J Med 2001, 345(23):1706-1707.
178. Gadducci A., Biglia N., Cosio S., et al. Gynaecologic challenging issues in the management of BRCA mutation carriers: oral contraceptives, prophylactic salpingo-oophorectomy and hormone replacement therapy. Gynecol Endocrinol 2010, 26(8):568-577.
179. Rice L.W. Hormone prevention strategies for breast, endometrial and ovarian cancers. Gynecol Oncol 2010, 118(2):202-207.
180. Oral contraceptives cut inherited cancer risk. Contracept Technol Update 1998, 19(11):146-147.
181. Jensen J.T., Speroff L. Health benefits of oral contraceptives. Obstet Gynecol Clin North Am 2000, 27(4):705-721.
182. Whittemore A.S., Balise R.R., Pharoah P.D., et al. Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations. Br J Cancer 2004, 91(11):1911-1915.
183. Narod S.A., Risch H., Moslehi R., et al. Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. NEngl J Med 1998, 339(7):424-428.
184. Kwon J.S., Tinker A., Pansegrau G., et al. Prophylactic salpingectomy and delayed oophorectomy as an alternative for BRCA mutation carriers. Obstet Gynecol 2013, 121(1):14-24.
185. Leblanc E., Narducci F., Farre I., et al. Radical fimbriectomy: a reasonable temporary risk-reducing surgery for selected women with a germ line mutation of BRCA 1 or 2 genes? Rationale and preliminary development. Gynecol Oncol 2011, 121(3):472-476.
186. Liede A., Karlan B.Y., Narod S.A. Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. JClin Oncol 2004, 22(4):735-742.
187. Friedman L.S., Gayther S.A., Kurosaki T., et al. Mutation analysis of BRCA1 andBRCA2 in a male breast cancer population. Am J Hum Genet 1997, 60(2):313-319.
188. Tai Y.C., Domchek S., Parmigiani G., et al. Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. JNatl Cancer Inst 2007, 99(23):1811-1814.
189. Agalliu I., Gern R., Leanza S., et al. Associations of high-grade prostate cancer with BRCA1 and BRCA2 founder mutations. Clin Cancer Res 2009, 15(3):1112-1120.
190. Cybulski C., Gorski B., Gronwald J., et al. BRCA1 mutations and prostate cancer in Poland. Eur J Cancer Prev 2008, 17(1):62-66.
191. van Asperen C.J., Brohet R.M., Meijers-Heijboer E.J., et al. Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. JMed Genet 2005, 42(9):711-719.
192. Kim D.H., Crawford B., Ziegler J., et al. Prevalence and characteristics of pancreatic cancer in families with BRCA1 and BRCA2 mutations. Fam Cancer 2009, 8(2):153-158.
193. Lynch H.T., Deters C.A., Snyder C.L., et al. BRCA1 and pancreatic cancer: pedigree findings and their causal relationships. Cancer Genet Cytogenet 2005, 158(2):119-125.
194. Couch F.J., Farid L.M., DeShano M.L., et al. BRCA2 germline mutations in male breast cancer cases and breast cancer families. Nat Genet 1996, 13(1):123-125.
195. Fentiman I.S., Fourquet A., Hortobagyi G.N. Male breast cancer. Lancet 2006, 367(9510):595-604.
196. Hahn S.A., Greenhalf B., Ellis I., et al. BRCA2 germline mutations in familial pancreatic carcinoma. JNatl Cancer Inst 2003, 95(3):214-221.
197. Murphy K.M., Brune K.A., Griffin C., et al. Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. Cancer Res 2002, 62(13):3789-3793.
198. Kirchhoff T., Kauff N.D., Mitra N., et al. BRCA mutations and risk of prostate cancer in Ashkenazi Jews. Clin Cancer Res 2004, 10(9):2918-2921.
199. Ozcelik H., Schmocker B., Di Nicola N., et al. Germline BRCA2 6174delT mutations in Ashkenazi Jewish pancreatic cancer patients. Nat Genet 1997, 16(1):17-18.
200. Cancer risks in BRCA2 mutation carriers. The Breast Cancer Linkage Consortium. JNatl Cancer Inst 1999, 91(15):1310-1316.
201. Euhus D.M., Robinson L. Genetic predisposition syndromes and their management. Surg Clin North Am 2013, 93(2):341-362.